Stay updated on Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial.

Sign up to get notified when there's something new on the Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial. page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial. page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    The clinical trial record is displayed in place of the access-denied error, with details about the breast cancer study, including its design, eligibility, measures, and participating locations.
    Difference
    100%
    Check dated 2026-11-08T14:52:17.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    The footer revision changed from v3.7.2 to v3.8.0; the study record is still replaced by a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T15:57:29.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    A sitewide banner announces NIH’s stated transition from “Artificial Intelligence” to “Super Intelligence” terminology under Executive Order 14434.
    Difference
    1%
    Check dated 2026-10-25T15:00:21.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.1 to v3.7.2; the page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-18T15:20:10.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.0 to v3.7.1 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-11T14:55:10.000Z thumbnail image
  7. Check
    63 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error page with its HTML markup, replacing the previous clinical trial content. Sponsor and trial-related sections and external links were removed, indicating the page is serving an error state rather than study details.
    Difference
    20%
    Check dated 2026-09-20T20:11:06.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial.

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial. page.